Pioneering- one of our core values and how it influences everything we do

Over the past forty years the proportion of people who survived for ten years after leukaemia diagnosis has increased more than six fold. Over the same period ten year survival has merely doubled for those with a brain tumour. This shows that something different, pioneering and innovative needs to be done.
The Brain Tumour Charity is at the forefront of the fight to defeat brain tumours, making a difference every day to the lives of people with a brain tumour and their families. We fund pioneering research to increase survival, raise awareness of the symptoms and effects of brain tumours and provide support for everyone affected to improve quality of life. We are relentless in the pursuit of our vision, seeking new ways to make a difference. We are determined to remain at the forefront of this disease, funding pioneering, innovative research that makes breakthroughs to save lives.

David has over 20 years’ experience in oncology research after gaining a degree in biochemistry from Brunel University. He undertook a PhD at University of London before joining Cancer Research UK as a postdoctoral researcher. David then led the biology at a company developing therapeutics to control the switching ‘on’ and ‘off’ of genes in cancer.

Up till now, David worked for Cancer Research Technology where he gained experience in technology assessment, protection, development and licensing. Whilst in this post, he introduced several innovative approaches to ensure the progression of discoveries towards patients, such as securing orphan designations, industry co-funding agreements and the establishment of industry-academia drug discovery alliances.
David has a passion for ensuring basic research is translated into the clinic for patient benefit and early diagnosis where tumours are spotted at a stage that is more easily treatable. He brings his collaborative approach to the brain tumour field and is determined to make a difference for those affected by these hard to treat tumours.